company background image
MNKD logo

MannKind NasdaqGM:MNKD Stock Report

Last Price

US$6.58

Market Cap

US$1.9b

7D

-4.1%

1Y

88.0%

Updated

26 Nov, 2024

Data

Company Financials +

MannKind Corporation

NasdaqGM:MNKD Stock Report

Market Cap: US$1.9b

MNKD Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. More details

MNKD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance3/6
Financial Health0/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

MannKind Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MannKind
Historical stock prices
Current Share PriceUS$6.58
52 Week HighUS$7.63
52 Week LowUS$3.17
Beta1.3
11 Month Change0.61%
3 Month Change11.53%
1 Year Change88.00%
33 Year Change42.12%
5 Year Change434.96%
Change since IPO-90.65%

Recent News & Updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 15

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

May 15
Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

MannKind to co-promote Thyquidity

Dec 17

Shareholder Returns

MNKDUS BiotechsUS Market
7D-4.1%4.0%2.0%
1Y88.0%18.0%32.4%

Return vs Industry: MNKD exceeded the US Biotechs industry which returned 18.3% over the past year.

Return vs Market: MNKD exceeded the US Market which returned 32.6% over the past year.

Price Volatility

Is MNKD's price volatile compared to industry and market?
MNKD volatility
MNKD Average Weekly Movement5.0%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: MNKD has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MNKD's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991413Michael Castagnawww.mannkindcorp.com

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).

MannKind Corporation Fundamentals Summary

How do MannKind's earnings and revenue compare to its market cap?
MNKD fundamental statistics
Market capUS$1.85b
Earnings (TTM)US$21.57m
Revenue (TTM)US$267.20m

84.1x

P/E Ratio

6.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MNKD income statement (TTM)
RevenueUS$267.20m
Cost of RevenueUS$75.07m
Gross ProfitUS$192.14m
Other ExpensesUS$170.57m
EarningsUS$21.57m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.078
Gross Margin71.91%
Net Profit Margin8.07%
Debt/Equity Ratio-108.6%

How did MNKD perform over the long term?

See historical performance and comparison